Table 1.
Study (year) | Tissue/cell line | Genes | GT/EGCG dose and duration of treatment (μmol/l, days) | Effect | Ref. |
---|---|---|---|---|---|
Fang et al. (2007) | Esophagus | p16, RARβ, hMLH1 and MGMT | 5–50 EGCG, 1-6 | Decreased DNMT1, gene reactivation | [55] |
Wong et al. (2011) | Immune T cells, Jurkat | FOXP3 | 2–10 EGCG, 1–2 | Decreased DNMT1 | [71] |
Kato et al. (2008) | Oral SCC9 and HSC3 | RECK tumor suppressor | 20–50 EGCG, 3–6 | Reversed hypermethylation, gene reactivation | [72] |
Gao et al. (2009) | Lung H460 and A549 | WIF-1 | 10–50 EGCG, 3 | Demethylation | [83] |
Li et al. (2010) | Breast MDAMB-231 | ER-α | 10 EGCG, 3 | Reversed hypermethylation, gene reactivation | [77] |
Nandakumar et al. (2011) | Skin A431 | p16(INK4a) and p21/Cip1 | 10 EGCG, 6 | Decreased DNMT1, gene reactivation | [75] |
Pandey et al. (2010) | Prostate | GSTP1 | 10 PolyE, 14 | Decreased DNMT1, gene reactivation | [84] |
Chuang et al. (2005) | T24, HT29 and PC3 | p16, RARb, MAGE-A1, MAGE-B2 and Alu | 20–30 EGCG, 6 | No effect | [85] |
Streseman et al. (2006) | TK6, Jurkat and KG-1 | TIMP3 | 2–50 EGCG, 3 | No effect | [86] |
EGCG: Epigallocatechin gallate; GT: Green tea; PolyE: Polyphenon E.